Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
16.89
Dollar change
+0.05
Percentage change
0.30
%
Index- P/E- EPS (ttm)-2.02 Insider Own6.89% Shs Outstand89.83M Perf Week-1.17%
Market Cap1.52B Forward P/E21.75 EPS next Y0.78 Insider Trans-1.17% Shs Float83.63M Perf Month34.58%
Income-160.28M PEG- EPS next Q-0.23 Inst Own56.21% Short Float12.52% Perf Quarter17.29%
Sales27.96M P/S54.26 EPS this Y78.11% Inst Trans-4.78% Short Ratio8.12 Perf Half Y57.26%
Book/sh0.92 P/B18.30 EPS next Y277.41% ROA-68.90% Short Interest10.47M Perf Year83.79%
Cash/sh1.17 P/C14.43 EPS next 5Y15.00% ROE-481.35% 52W Range8.00 - 17.47 Perf YTD19.62%
Dividend Est.- P/FCF- EPS past 5Y4.78% ROI-131.17% 52W High-3.32% Beta1.59
Dividend TTM- Quick Ratio3.36 Sales past 5Y-40.99% Gross Margin96.97% 52W Low111.12% ATR (14)0.74
Dividend Ex-Date- Current Ratio3.64 EPS Y/Y TTM11.68% Oper. Margin-492.97% RSI (14)62.06 Volatility4.02% 6.43%
Employees154 Debt/Eq0.40 Sales Y/Y TTM- Profit Margin-573.17% Recom1.00 Target Price22.90
Option/ShortYes / Yes LT Debt/Eq0.39 EPS Q/Q30.22% Payout- Rel Volume0.40 Prev Close16.84
Sales Surprise6.96% EPS Surprise-13.76% Sales Q/Q- EarningsMar 04 BMO Avg Volume1.29M Price16.89
SMA205.78% SMA5013.77% SMA20026.00% Trades Volume510,834 Change0.30%
Date Action Analyst Rating Change Price Target Change
Mar-05-24Reiterated Oppenheimer Outperform $27 → $29
Mar-05-24Reiterated Needham Buy $20 → $22
Mar-05-24Reiterated H.C. Wainwright Buy $21 → $25
Feb-06-24Initiated UBS Buy $21
Nov-30-22Upgrade Jefferies Hold → Buy $6.50 → $11
Aug-10-22Downgrade Jefferies Buy → Hold $6 → $8
Jul-28-22Resumed Craig Hallum Buy $15.50 → $12
May-26-22Downgrade Stifel Buy → Hold $9 → $2
Sep-23-21Initiated Needham Buy $17
Jul-31-20Initiated Oppenheimer Outperform $19
Mar-05-24 10:25AM
08:00AM
Mar-04-24 03:37PM
06:30AM
Feb-26-24 08:00AM
08:00AM Loading…
Feb-07-24 08:00AM
Jan-18-24 10:35AM
Jan-15-24 12:00PM
09:55AM
Jan-12-24 08:32AM
Jan-08-24 07:00AM
Nov-10-23 12:16PM
Nov-08-23 07:07AM
07:00AM
Nov-07-23 08:00AM
08:00AM Loading…
Oct-30-23 08:00AM
Oct-20-23 08:00AM
Oct-05-23 08:00AM
Sep-26-23 11:52AM
Aug-31-23 10:16PM
08:00AM
Aug-13-23 08:09AM
Aug-11-23 08:28AM
07:01AM
Aug-10-23 10:32PM
Aug-09-23 07:07AM
07:00AM
Aug-03-23 04:05PM
Aug-02-23 08:00AM
Jul-28-23 02:56PM
04:05PM Loading…
Jul-20-23 04:05PM
Jul-06-23 04:05PM
Jul-03-23 04:50PM
Jun-23-23 09:57AM
Jun-22-23 08:00AM
Jun-20-23 10:10AM
Jun-14-23 08:00AM
Jun-13-23 08:00AM
Jun-06-23 04:05PM
Jun-05-23 07:00AM
Jun-01-23 08:00AM
May-31-23 04:00PM
May-21-23 08:20AM
May-05-23 03:44PM
May-04-23 06:14PM
04:05PM
May-03-23 04:05PM
07:24AM
May-01-23 01:20PM
Apr-20-23 04:05PM
Apr-10-23 08:00AM
Apr-05-23 07:44PM
Apr-03-23 04:05PM
Mar-30-23 07:00AM
Mar-29-23 09:27PM
09:24PM
04:13PM
04:01PM
Mar-22-23 07:00AM
Mar-21-23 04:05PM
Mar-02-23 07:00AM
Feb-28-23 10:37AM
Feb-24-23 04:16PM
03:51PM
Feb-16-23 04:05PM
Feb-08-23 08:00AM
Feb-03-23 08:00AM
Jan-24-23 08:00AM
Jan-23-23 04:05PM
Jan-10-23 04:05PM
Dec-19-22 04:05PM
Dec-01-22 04:05PM
Nov-26-22 07:49AM
Nov-22-22 08:00AM
Nov-21-22 04:05PM
02:32PM
08:40AM
Nov-18-22 02:45PM
Nov-10-22 08:00AM
Nov-09-22 07:30AM
Nov-07-22 04:05PM
Nov-02-22 04:05PM
Oct-24-22 04:05PM
Oct-16-22 10:25AM
Sep-22-22 08:00AM
Sep-07-22 08:00AM
Aug-09-22 08:00AM
07:00AM
Aug-05-22 09:55AM
Aug-02-22 08:00AM
Jul-19-22 07:00AM
Jun-30-22 08:09AM
Jun-29-22 04:05PM
Jun-03-22 08:00AM
Jun-02-22 08:00AM
06:07AM
May-26-22 09:09AM
May-19-22 08:00AM
May-18-22 08:00AM
May-09-22 10:05AM
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCHUGH THOMAS SChief Financial OfficerJan 16 '24Buy14.502,00029,00080,500Jan 16 04:36 PM
McCamish Mark AnthonyDirectorDec 28 '23Sale14.5375,0001,089,75067,025Dec 29 04:15 PM
MCHUGH THOMAS SChief Financial OfficerAug 14 '23Buy14.452,00028,90078,500Aug 14 05:56 PM
McCamish Mark AnthonyDirectorAug 11 '23Sale14.9328,975432,614142,025Aug 15 04:13 PM
Glass Geoffrey MichaelDirectorAug 10 '23Buy13.4014,000187,60059,000Aug 11 04:00 PM
Divis Gregory JChief Executive OfficerAug 10 '23Buy13.2010,000131,997159,100Aug 10 06:45 PM
Ende Eric JDirectorMay 18 '23Buy13.9313,000181,100167,900May 19 04:16 PM
Palczuk LindaDirectorMay 09 '23Buy14.762,50036,90052,400May 10 04:12 PM